MX2022000176A - Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas. - Google Patents

Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.

Info

Publication number
MX2022000176A
MX2022000176A MX2022000176A MX2022000176A MX2022000176A MX 2022000176 A MX2022000176 A MX 2022000176A MX 2022000176 A MX2022000176 A MX 2022000176A MX 2022000176 A MX2022000176 A MX 2022000176A MX 2022000176 A MX2022000176 A MX 2022000176A
Authority
MX
Mexico
Prior art keywords
methods
compositions
detection
myeloproliferative diseases
calr mutations
Prior art date
Application number
MX2022000176A
Other languages
English (en)
Inventor
Yongbao Wang
Daniel Jones
Original Assignee
Quest Diagnostics Invest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Inc filed Critical Quest Diagnostics Invest Inc
Publication of MX2022000176A publication Critical patent/MX2022000176A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proveen aquí métodos y composiciones para la detección de mutaciones de línea germinal de deleción en marco del gen CALR. También se proveen métodos para determinar el pronóstico de enfermedades mieloproliferativas y la probabilidad de desarrollar mutaciones somáticas en genes implicados en la ruta JAK-STAT.
MX2022000176A 2015-04-23 2017-10-23 Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas. MX2022000176A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562151742P 2015-04-23 2015-04-23

Publications (1)

Publication Number Publication Date
MX2022000176A true MX2022000176A (es) 2022-02-21

Family

ID=57144325

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017013623A MX2017013623A (es) 2015-04-23 2016-04-22 Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.
MX2022000176A MX2022000176A (es) 2015-04-23 2017-10-23 Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017013623A MX2017013623A (es) 2015-04-23 2016-04-22 Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.

Country Status (8)

Country Link
US (3) US10519509B2 (es)
EP (1) EP3286336A4 (es)
CN (1) CN107949643A (es)
BR (1) BR112017022779B1 (es)
CA (1) CA2983820A1 (es)
HK (1) HK1254254A1 (es)
MX (2) MX2017013623A (es)
WO (1) WO2016172505A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018134260A1 (en) * 2017-01-18 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
CN107164474B (zh) * 2017-05-22 2020-09-04 复旦大学附属华山医院 一种检测calr基因2型突变的引物组合物及试剂盒
CN107679366A (zh) * 2017-08-30 2018-02-09 武汉古奥基因科技有限公司 一种基因组变异数据的计算方法
CN114302967A (zh) * 2019-08-30 2022-04-08 东洋钢钣株式会社 用于评价骨髓增殖性肿瘤相关基因突变的试剂盒
CN113764044B (zh) * 2021-08-31 2023-07-21 华南理工大学 一种构建骨髓增生异常综合征进展基因预测模型的方法
CN115141886B (zh) * 2022-06-28 2023-06-06 厦门艾德生物医药科技股份有限公司 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
WO2011069004A1 (en) 2009-12-04 2011-06-09 Quest Diagnostics Investments Incorporated Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
US9371570B2 (en) * 2013-09-16 2016-06-21 CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Mutant calreticulin for the diagnosis of myeloid malignancies

Also Published As

Publication number Publication date
US10519509B2 (en) 2019-12-31
CN107949643A (zh) 2018-04-20
US20220364180A1 (en) 2022-11-17
EP3286336A4 (en) 2018-11-14
WO2016172505A2 (en) 2016-10-27
US20200165688A1 (en) 2020-05-28
BR112017022779B1 (pt) 2024-04-30
BR112017022779A2 (pt) 2018-07-17
HK1254254A1 (zh) 2019-07-12
CA2983820A1 (en) 2016-10-27
EP3286336A2 (en) 2018-02-28
WO2016172505A3 (en) 2016-12-08
MX2017013623A (es) 2018-07-06
US20160312303A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
MX2022000176A (es) Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
CY1124886T1 (el) Χιμαιρικοι υποδοχεις αντιγονου bcma
EP3704640A4 (en) PREDICTION OF CANCER-RELATED PATHOGENIC EFFECTS OF SOMATIC MUTATIONS USING DEEP LEARNING METHODS
EP3322815A4 (en) Compositions and methods for detection of genetic deafness gene mutation
EA201891317A3 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
EP4219532A3 (en) Compositions and methods for transient gene therapy with enhanced stability
PH12016502162A1 (en) Multiplex gene editing in swine
MX2018009750A (es) Composiciones potenciadoras de vcn y métodos para su uso.
MA41044A (fr) Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3186375A4 (en) NEW CAS9 PROTEINS AND GUIDING ELEMENTS FOR DNA TARGETING AND THE GENOME EDITION
MY192927A (en) Fused bicyclic compounds for the treatment of disease
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
EP3337509A4 (en) Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
EP4084806A4 (en) NOVEL ANUCLEATED CELLS FOR DRUG DELIVERY AND METHODS OF USE
SG11202105645PA (en) Ancestry-specific genetic risk scores
GB202000014D0 (en) DDX24 gene mutation and use thereof
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
MX2021000899A (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.
IL282752A (en) Methods for altering gene expression for genetic disorders
EA202091567A1 (ru) Химерные белки мти
IL247752A0 (en) Compositions and methods for modulating gene expression for site-directed mutagenesis
EP3291818A4 (en) Compositions and methods for delivering therapeutic agents into the colon
EP3442544A4 (en) IMPROVED GENE RELEASE PROCEDURES
EP3847182A4 (en) Methods of using genetic markers associated with endometriosis